Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide and Tirzepatide are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Semaglutide and Tirzepatide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Both Semaglutide and Tirzepatide are closely matched — the best choice depends on your specific health goals.
No known interactions between Semaglutide and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.